CMPS
Compass, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveCMPS (Compass Pathways) beat Q3 loss estimates and confirmed COMP360 psilocybin therapy on track for H1 2027 launch, but competitive pressure from Usona Institute's FDA filing briefly rattled the stock; analyst sentiment improved from 'strong sell' to 'hold'/'buy' by mid-November despite mixed price targets ($10–$65 range). COMP (Compass, Inc. real estate) delivered record Q3 results with $3.9B revenue (+11.6% YoY), $306M adjusted EBITDA, and strong free cash flow ($240M), significantly outperforming a down housing market.
Red flags
- •CMPS: Significant analyst price-target divergence ($10–$65 range) suggests high uncertainty around COMP360 commercialization prospects
- •CMPS: Competitive psilocybin therapy filing by Usona Institute triggered sector selloff and 'worst day in months' volatility
- •CMPS: Rolling NDA submission timeline ('within two weeks' as of Nov 3) is aggressive and execution-dependent for H1 2027 launch
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| D1 Capital | SC 13G | NEW | 6.1% | +7.8% vs SPY +4.6% abs | 2026-11-16 | ↗ |